Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA): Price and Financial Metrics

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Today's Latest Price: $11.96 USD

0.46 (4.00%)

Updated Jan 15 7:00pm

Add TEVA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TEVA Stock Summary

  • TEVA has a market capitalization of $12,603,672,894 -- more than approximately 84.75% of US stocks.
  • TEVA's went public 30.83 years ago, making it older than 84.17% of listed US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TEVA comes in at 15.87% -- higher than that of 88.28% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Teva Pharmaceutical Industries Ltd are OC, ATO, IMO, ASH, and VST.
  • TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to

TEVA Stock Price Chart Interactive Chart >

Price chart for TEVA

TEVA Price/Volume Stats

Current price $11.96 52-week high $13.76
Prev. close $11.50 52-week low $6.25
Day low $11.50 Volume 12,430,400
Day high $12.06 Avg. volume 12,239,970
50-day MA $10.08 Dividend yield N/A
200-day MA $10.53 Market Cap 13.06B

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio

Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.

TEVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$11.96$0.44 -96%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Teva Pharmaceutical Industries Ltd. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 7th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Teva Pharmaceutical Industries Ltd ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is -4.72 -- which is good for besting only 13.34% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The company's compound free cash flow growth rate over the past 4.74 years comes in at -0.29%; that's greater than merely 5.5% of US stocks we're applying DCF forecasting to.
  • 33% of the company's capital comes from equity, which is greater than just 9.87% of stocks in our cash flow based forecasting set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

NVST, SXTC, INFU, LUMO, and OSMT can be thought of as valuation peers to TEVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

TEVA Latest News Stream

Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream

Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about Teva Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Business and Trading Update (Shield Therapeutics plc)

) Shield Therapeutics plc ("Shield" or the "Group" or the "Company") Business and trading update London, UK, 15 January 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), provides a business and unaudited trading update for the year ended 31 December 2020. Operational highlights Feraccru® 2020 sales volumes in Europe increased by ~70% year-on-year China IND application submitted First stage of paediatric study plan completed Teva challenge to Shield's European patents withdrawn Shield continues to evaluate options for launching…

World News Network | January 15, 2021

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability of a generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women t

Business Wire | January 14, 2021

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on 39th Annual JP Morgan Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (TEVA) 39th Annual JP Morgan Healthcare Conference January 12, 2021 10:00 A.M. ET Company Participants Kåre Schultz - President and Chief Executive Officer Eli Kalif - EVP and CFO Conference Call Participants Chris Schott - J.P. Morgan Presentation Chris Schott Good morning, everybody. I'm Chris Schott...

SA Transcripts on Seeking Alpha | January 13, 2021

Parkinson’s Disease Therapeutic Market by Sub segments, Industry Demands and Trends, Market Insight and Forecast by 2020 | Salix Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Novartis AG

Parkinson’s Disease Therapeutic Market Report evaluated the historical and current performance of the market, especially highlighting the key trends and growth opportunities. Parkinson’s Disease Therapeutic market report discussed this scenario of market size with reference to volume and share. Parkinson’s

OpenPR | January 13, 2021

Overactive Bladder Treatment Market Revenue Growth By 2027 | Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas

CMI published a business research report on “Overactive Bladder Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2020–2027”. Overactive Bladder Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy

OpenPR | January 12, 2021

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo 19.48%
3-mo 26.16%
6-mo 1.87%
1-year N/A
3-year -42.22%
5-year -79.67%
YTD 23.94%
2020 -1.53%
2019 -36.45%
2018 -18.63%
2017 -46.23%
2016 -43.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9444 seconds.